2022Prostate Cancer and Prostatic DiseasesOpen access

Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Scott T. Tagawa, Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, Daniel J. George

Open full text 1 citations

Abstract

Authors and Affiliations Weill Cornell Medicine, New York, NY, USA Scott T. Tagawa Pfizer Inc., New York, NY, USA Krishnan Ramaswamy & Jack Mardekian STATinMED Research, Plano, TX, USA Ahong Huang & Li Wang Astellas Pharma Inc., Northbrook, IL, USA Neil M. Schultz Pfizer AB., Sollentuna, Sweden Rickard Sandin Pfizer Inc., San Francisco, CA, USA Stanislav Lechpammer Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA Daniel J. George Authors Scott T. Tagawa View author publications You can also search for this author in PubMed Google Scholar Krishnan Ramaswamy View author publications You can also search for this author in PubMed Google Scholar Ahong Huang View author publications You can also search for this author in PubMed Google Scholar Jack Mardekian View author publications You can also search for this author in PubMed Google Scholar Neil M. Schultz View author publications You can also search for this author in PubMed Google Scholar Li Wang View author publications You can also search for this author in PubMed Google Scholar Rickard Sandin View author publications You can also search for this author in PubMed Google Scholar Stanislav Lechpammer View author publications You can also search for this author in PubMed Google Scholar Daniel J. George View author publications You can also search for this author in PubMed Google Scholar Corresponding author Correspondence to Krishnan Ramaswamy .

Open-access reader

About this research paper

What this paper is about

Authors and Affiliations Weill Cornell Medicine, New York, NY, USA Scott T. Tagawa Pfizer Inc., New York, NY, USA Krishnan Ramaswamy & Jack Mardekian STATinMED Research, Plano, TX, USA Ahong Huang & Li Wang Astellas Pharma Inc., Northbrook, IL, USA Neil M. Schultz Pfizer AB., Sollentuna, Sweden Rickard Sandin Pfizer Inc., San Francisco, CA, USA Stanislav Lechpammer Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA Daniel J. George Authors Scott T. Tagawa View author publications You can also search for this author in PubMed Google Scholar Krishnan Ramaswamy View author publications You can also search for this author in PubMed Google Scholar Ahong Huang View author publications You can also search for this author in PubMed Google Scholar Jack Mardekian View author publications You can also search for this author in PubMed Google Scholar Neil M. Schultz View author publications You can also search for this author in PubMed Google Scholar Li Wang View author publications You can also search for this author in PubMed Google Scholar Rickard Sandin View author publications You can also search for this author in PubMed Google Scholar Stanislav Lechpammer View author publications You can also search for this author in PubMed Google Scholar Daniel J. George View author publications You can also search for this author in PubMed Google Scholar Corresponding author Correspondence to Krishnan Ramaswamy .

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Authors and Affiliations Weill Cornell Medicine, New York, NY, USA Scott T. Tagawa Pfizer Inc., New York, NY, USA Krishnan Ramaswamy & Jack Mardekian STATinMED Research, Plano, TX, USA Ahong Huang & Li Wang Astellas Pharma Inc., Northbrook, IL, USA Neil M. Schultz Pfizer AB., Sollentuna, Sweden Rickard Sandin Pfizer Inc., San Francisco, CA, USA Stanislav Lechpammer Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA Daniel J. George Authors Scott T. Tagawa View author publications You can also search for this author in PubMed Google Scholar Krishnan Ramaswamy View author publications You can also search for this author in PubMed Google Scholar Ahong Huang View author publications You can also search for this author in PubMed Google Scholar Jack Mardekian View author publications You can also search for this author in PubMed Google Scholar Neil M. Schultz View author publications You can also search for this author in PubMed Google Scholar Li Wang View author publications You can also search for this author in PubMed Google Scholar Rickard Sandin View author publications You can also search for this author in PubMed Google Scholar Stanislav Lechpammer View author publications You can also search for this author in PubMed Google Scholar Daniel J. George View author publications You can also search for this author in PubMed Google Scholar Corresponding author Correspondence to Krishnan Ramaswamy .

Key concepts: Enzalutamide, Abiraterone acetate, Medicine, Prostate cancer, Oncology, Abiraterone, Internal medicine, Chemotherapy

Related papers

Back to paper searchBrowse research topicsOriginal source
Correction: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate — Research Paper | ScholarLens